NCT01632995View on ClinicalTrials.gov

Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics

NACompletedINTERVENTIONAL

Enrollment

557

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

HIV Infections

Interventions

DRUG

FTC 200 mg/TDF 300 mg fixed-dose combination tablet

Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.

Trial Locations (3)

20009

Whitman Walker Non-network CRS, Washington D.C.

33136

Miami PrEP Non-Network CRS, Miami

94103

SF City Clinic Non-Network CRS, San Francisco

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01632995 - Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics | Biotech Hunter | Biotech Hunter